![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Updated follow-up analysis in the REP 401 protocol: treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated
interferon alfa-2a
|
|
|
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
![0518181](../images%20/051818/051718-1/0518181.gif)
![0518182](../images%20/051818/051718-1/0518182.gif)
![0518183](../images%20/051818/051718-1/0518183.gif)
![0518184](../images%20/051818/051718-1/0518184.gif)
![0518185](../images%20/051818/051718-1/0518185.gif)
![0518186](../images%20/051818/051718-1/0518186.gif)
![0518187](../images%20/051818/051718-1/0518187.gif)
![0518188](../images%20/051818/051718-1/0518188.gif)
![0518189](../images%20/051818/051718-1/0518189.gif)
![05181810](../images%20/051818/051718-1/05181810.gif)
![05181811](../images%20/051818/051718-1/05181811.gif)
![05181812](../images%20/051818/051718-1/05181812.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|